COMPANY OF THE YEAR

Why Walmart is Yahoo Finance's 2024 winner

Stuttgart - Delayed Quote EUR

Rapt Therapeutics Inc. (US75382E1091.SG)

0.8500

-0.0050

(-0.58%)

As of 8:04:51 AM GMT+1. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for US75382E1091.SG

RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull

RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull

RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now

RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now

RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability

RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability

Should You Sell Your Stake in RAPT Therapeutics (RAPT)?

Should You Sell Your Stake in RAPT Therapeutics (RAPT)?

Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround

Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround

Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks

Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks

RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview

What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?

What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?

RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials

What Makes RAPT Therapeutics (RAPT) an Investment Choice?

What Makes RAPT Therapeutics (RAPT) an Investment Choice?